
Nuvalent (NUVL) Stock Forecast & Price Target
Nuvalent (NUVL) Analyst Ratings
Bulls say
Nuvalent is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer patients. With FDA acceptance of its NDA for neladalkib in ALK+ NSCLC patients and promising data on its lead candidate zidesamtinib, we are optimistic about the company's future. We maintain an OUTPERFORM rating and a PT of $125 based on a sum-of-parts valuation with discounted sales multiples for NVL-520 and NVL-655, and acknowledge potential risks from clinical results and competition.
Bears say
Nuvalent is demonstrating strong potential with their small molecule treatments for cancer, but the company's negative financials, including a high risk-adjusted discount rate and low sales projections, suggest that they may struggle to meet their goals and achieve profitability in the near future. The recent analysis of their ARROS-1 study also raises concerns about the effectiveness of their treatment in heavily pretreated patients. These factors contribute to a negative outlook on Nuvalent's stock.
This aggregate rating is based on analysts' research of Nuvalent and is not a guaranteed prediction by Public.com or investment advice.
Nuvalent (NUVL) Analyst Forecast & Price Prediction
Start investing in Nuvalent (NUVL)
Order type
Buy in
Order amount
Est. shares
0 shares